8-K

from 8-K 4 pages 8-K

06/03/24

EX-99.1

from 8-K 5 pages Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

06/03/24

EX-99.2

from 8-K 35 pages CLN-619 and Zipalertinib Updates at ASCO June 2024

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s1.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s2.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s3.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s4.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s5.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s6.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s7.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s8.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s9.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s10.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s11.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s12.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s13.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s14.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s15.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s16.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s17.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s18.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s19.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s20.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s21.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s22.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s23.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s24.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s25.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s26.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s27.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s28.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s29.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s30.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s31.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s32.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s33.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s34.jpg

06/03/24

GRAPHIC

from 8-K cgem-ex99_2s35.jpg

06/03/24